RNB in UPUMS SAIFAI

STUDY TO EVALUATE EFFECT OF RNB (RAJ NIRVAN BATI) AYURVEDIC MEDICINE IN COVID-19 ILLNESS

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025852

Enrollment

Registered

2020-06-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: AYURVEDIC DRUG RNB: DAIL DOSE OF RNB(125mg)BD IS GIVEN TO COVID 19 POSITIVE PATIENTS WHO FULL FILL TH E INCLUSION AND EXCLUSION CRITERIA for 10 days Control Intervention1: NOT APPLICABL

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age>=18years 2.Laboratory(RT-PCR)positiveofSARS- CoV-2

Exclusion criteria

Exclusion criteria: 1.Patient refuse for consent. 2.Criticalyil patient (Sp02 3.Patient with deranged renal function (S. creatinine >1.5mg/dl) 4.Pregnancy&lactating.

Design outcomes

Primary

Measure	Time frame
1)Clinical improvement of symptoms which was their at the time of admission 2)microbiological: microbiological clearance of virus by nasal swab and throat swab by RTPCRTimepoint: after 10 day of intervetion	—

Secondary

Measure	Time frame
to study on renal safety Timepoint: 5th 10th day of starting treatment	—

Countries

India

Contacts

Public ContactDr Raj Kumar

Department of Neurosurgery

ramakant.gsvm@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026